Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA12 | O43570 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.49 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424317 | 0.82 | MAPT (0.74) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL16057183 | 0.82 | CA1 (1.00) | CA1CA2CA12CA9MAPT | |
| SCHEMBL18850964 | 0.82 | CA12 (0.70) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL28023107 | 0.80 | L3MBTL1 (0.58) | CA1CA2CA12CA9MAPT | |
| SCHEMBL28023108 | 0.80 | CA12 (0.57) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL10067645 | 0.79 | CA12 (0.66) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL19777840 | 0.79 | CA12 (0.66) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL18851200 | 0.78 | CA12 (0.64) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL18851155 | 0.78 | CA12 (0.64) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL5550330 | 0.77 | HDAC1 (0.67) | CA1CA2CA12CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2023059583-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8097636-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097636-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-17 | — | — | US | disclosed |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2009064752-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-4794196-A | N-aminoalkylperfluoroalkanoylaminobenzene-sulfonamide anti-arrhythmic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-12-27 | — | — | US | disclosed |
| EP-0025108-B1 | MAYTANSINOIDS, THEIR PRODUCTION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-02-09 | — | — | EP | disclosed |
| US-4264596-A | ANTITUMOR AGENTS, MICROBIOCIDES, MITOSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| EP-0025108-A1 | Maytansinoids, their production and therapeutic compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | CA1 1084/4885CA2 192/4885CA12 3362/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | CA1 1084/4885CA2 192/4885CA12 3362/4885 |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | CA1 3810/4885CA2 3204/4885CA12 3015/4885 |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | TRPV1, TRPV5, TRPA1 | CA1 2348/4885CA2 255/4885CA12 4600/4885 |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | CA1 1084/4885CA2 192/4885CA12 3362/4885 |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | CA1 3345/4885CA2 3031/4885CA12 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.